Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

36.4%

8 terminated/withdrawn out of 22 trials

Success Rate

52.9%

-33.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

89%

8 of 9 completed trials have results

Key Signals

1 recruiting8 with results6 terminated

Enrollment Performance

Analytics

Phase 1
9(45.0%)
Phase 2
7(35.0%)
N/A
4(20.0%)
20Total
Phase 1(9)
Phase 2(7)
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT06778837Completed

Lymphedema Sensor Technology Development Study

Role: collaborator

NCT03513484Phase 1Active Not Recruiting

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT05056077Not ApplicableRecruiting

Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)

Role: collaborator

NCT02495376Not ApplicableCompleted

Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology

Role: collaborator

NCT01465659Phase 1Completed

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Role: collaborator

NCT01687673Phase 2Completed

Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Role: collaborator

NCT01163786Phase 2Terminated

A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD

Role: collaborator

NCT01473940Phase 1Completed

Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Role: collaborator

NCT01476410Phase 2Unknown

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Role: collaborator

NCT01259089Phase 1Completed

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Role: collaborator

NCT00369707Phase 2Completed

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

Role: collaborator

NCT00372905Phase 1Terminated

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Role: collaborator

NCT00089284Phase 1Terminated

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Role: collaborator

NCT01259076Terminated

Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer

Role: collaborator

NCT00004903Phase 2Unknown

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Role: lead

NCT00005607Phase 2Unknown

Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus

Role: lead

NCT01009502Phase 1Terminated

Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Role: collaborator

NCT01060514Phase 1Terminated

Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Role: collaborator

NCT01074385Not ApplicableCompleted

Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making

Role: collaborator

NCT00080613Phase 2Withdrawn

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

Role: lead